Who are Zurzuvae's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ztalmy, Zulresso, ZULRESSO®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zuranolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Zurzuvae — Competitive Intelligence Brief

Zurzuvae (ZURANOLONE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]. Area: Neuroscience.

marketed Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] GABA A receptor alpha-4/beta-3/delta Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Zurzuvae (ZURANOLONE) — Biogen. Zurzuvae works by binding to the GABA A receptor, enhancing the inhibitory effects of GABA to calm overactive neurons.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zurzuvae TARGET	ZURANOLONE	Biogen	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-4/beta-3/delta	2023-01-01
Ztalmy	GANAXOLONE	Marinus	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-2/beta-1/gamma-2	2022-01-01
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
ZULRESSO®	ZULRESSO®	Supernus Pharmaceuticals, Inc.	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] class)

Biogen · 1 drug in this class
Marinus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zurzuvae — Competitive Intelligence Brief. https://druglandscape.com/ci/zuranolone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab